Diffuse Parenchymal Lung Diseases - Aetiology and Clinical Profile: A Prospective Study
Authors/Creators
- 1. Assistant Professor, Department of Pulmonary Medicine, Katihar Medical College and Hospital, Katihar, Bihar
- 2. Professor and Head of Department, Department of Pulmonary Medicine, Katihar Medical College and Hospital, Katihar, Bihar
Description
Background: A complex combination of diffuse parenchymal lung conditions, interstitial lung disease is characterized by restrictive physiology, decreased gas perfusion, inflammation of the lung parenchyma, and fibrosis. The pulmonary interstitium, which is made up of the connective tissue space between the alveolar epithelial cells and the nearby capillary endothelial cells, is primarily responsible for the pathophysiology of interstitial lung disease. Methods: The study was conducted from July 2022 to December 2022 in the department of Respiratory Medicine at Varun Arjun Medical College, Banthra, and Shahjahanpur. Total 60 patients, 36 male and 24 female included in this study. The male female ratio 1.5:1. Results: Exertional dyapoea was the most common presenting symptom; second most common symptom was nonproductive cough. COPD was the commonest comorbid illness, second commonest comorbid condition absorbed was mellitus. Out of the 36 men, 25 were Smokers (42%) of the 19 Patients with IPF 16 were smokers. Average smoking index was found to be 180. 21.58% patients had upper zone predominance in chest x- ray. 4 out of 60 patients had mid zone perihilar distribution of lesion. 29 out of 60 patients had lower zone predominance. Spirometry showed restrictive in 86 % of Patients. Conclusion: The profile of ILDs with their demographic, clinical and outcome data were analyzed and compared with other regional and global studies. The results recognized certain similarities and differences compared to other reports, formulating a distinctive study among others. Idiopathic interstitial pneumonias were the commonest type of ILD in studied sample, followed closely by secondary ILDs.
Abstract (English)
Background: A complex combination of diffuse parenchymal lung conditions, interstitial lung disease is characterized by restrictive physiology, decreased gas perfusion, inflammation of the lung parenchyma, and fibrosis. The pulmonary interstitium, which is made up of the connective tissue space between the alveolar epithelial cells and the nearby capillary endothelial cells, is primarily responsible for the pathophysiology of interstitial lung disease. Methods: The study was conducted from July 2022 to December 2022 in the department of Respiratory Medicine at Varun Arjun Medical College, Banthra, and Shahjahanpur. Total 60 patients, 36 male and 24 female included in this study. The male female ratio 1.5:1. Results: Exertional dyapoea was the most common presenting symptom; second most common symptom was nonproductive cough. COPD was the commonest comorbid illness, second commonest comorbid condition absorbed was mellitus. Out of the 36 men, 25 were Smokers (42%) of the 19 Patients with IPF 16 were smokers. Average smoking index was found to be 180. 21.58% patients had upper zone predominance in chest x- ray. 4 out of 60 patients had mid zone perihilar distribution of lesion. 29 out of 60 patients had lower zone predominance. Spirometry showed restrictive in 86 % of Patients. Conclusion: The profile of ILDs with their demographic, clinical and outcome data were analyzed and compared with other regional and global studies. The results recognized certain similarities and differences compared to other reports, formulating a distinctive study among others. Idiopathic interstitial pneumonias were the commonest type of ILD in studied sample, followed closely by secondary ILDs.
Files
IJPCR,Vol16,Issue3,Article83.pdf
Files
(625.2 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:6a413aedacccbf3556689693ec9ae841
|
625.2 kB | Preview Download |
Additional details
Dates
- Accepted
-
2024-02-26
Software
- Repository URL
- http://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue3,Article83.pdf
- Development Status
- Active
References
- 1. Colby TV, Swenson SI. Anatomic distribution and histopathologic patterns in diffuse lung disease. Correlation with HRCT. Thoracic Imaging 1996; 11:1-26. 2. Gaensler EA, Corrington CB, Coutu RE, Fitzgerald MX. Radiographic physiologic pathologic correlation in interstitial pneumonias. Prog Respir 1975; 8: 223-241. 3. Roelandt M, Demedts M, Callebaut W et al. Epidemiology of interstitial lung disease (ILD) in Flanders: Registration by pneumologists in 1992-1994. Working group ILD, VRGT. Vereniging voor Respiratoire Gezondheidszorg en Tuberculosebestrijding Act Clin Belg 1995; 50:260-268. 4. Hamman L, Rich AR. Clinical pathologic conference. Int Clin 1933; 1:196-231. 5. Reghu G, Interstitial lung disease: A diagnostic approach. Are CT scan and lung biopsy indicated in every patient? Am J Respir Crit Care Med 1995; 151: 909-914. 6. Schwarz MI, King TE. Interstitial Lung Disease, 2nd. Ed. St. Louis, Mosby-Year book, 1993. 7. Tung KT, Wells AU, Rubens MB et al. Accuracy of the typical computed tomographic appearances of fibrosing alveolitis Thorax 1993; 48: 334-338. 8. Wells AU, Hansell DM, Rubens MB et al. The predictive value of appearances on thin-section tomography in fibrosing alveolitis. Am Rev Respir Dis 1993, 148: 1076-1082. 9. Orens JB, Kazerooni EA, Martinez FJ et al. The sensitivity of high resolution CT in detecting idiopathic pulmonary fibrosis proved by open lung biopsy. A prospective study. Chest 1995, 108: 019-115. 10. Carrington CB, Gaensier EA. Coutu RE et al. Natural history and treated course of usual and desquamative interstitial pneumonia. New Engl J Med. 1978; 298: 801-809. 11. Agusti C, Xaubet A, Agusti AGN et al: Clinical and functional assessment of patients with idiopathic pulmonary fibrosis. Results of a 3 year follow up. Eur. Resp. J 1994; 7:643-650. 12. Panos RJ, King TE Jr. Idiopathic pulmonary fibrosis, in Lynch JP III, DeRemee RA (eds.), Immunologically Mediated Pulmonary Disease. Philadelphia, JB Lippincott, 1991, pp1- 39. 13. Harris-Eze AQ, Sridhar G, Clemens RE et al. Oxygen improves maximal exercise performance in interstitial lung disease. Am J Respir Crit Care Med 1994; 150:1616-1622. 14. Peterson MW, Nugent KM, Jolles H. Uniformity of bronchoalveolar lavage in patients with pulmonary sarcoidosis. Am Rev Respir Dis 1988; 137: 79-84. 15. Holt RM, Schmidt RA, Godwin JD, Raghu G. High resolution CT in respiratory bronchiolitis-associated interstitial lung disease. J Comput Tomogr 1993; 17, 46-50. 16. Johnson MA, Kwan S, Snell NJ et al. Randomised controlled trial comparing prenisolone alone with cyclophosphamide and low dose prednisolone in combination with cryptogenic fibrosing alveolotis. Thorax 1989; 44: 280- 288. 17. Meier-Sydow J, Weiss SM, Buhl R et al. Idiopathic pulmonary fibrosis. Current concepts and challenges in management Semin Respir Crit Care Med 1994, 15: 77-96. 18. Epler Gr, Colby TV, Mc Cloud JC et al. Bronchiolitis obliterans organizing pneumonia NEJM 1985; 312-152. 19. Remy-Jardin M, Giraud F, Remy J et al. Importance of ground-glass attenuation in chronic diffuse infiltrative lung disease Pathologic-CT correlation. Radiology 1993; 189: 693-698. 20. Johnson MA, Kwan S, Snell NJ et al. Randomized controlled trial comparing prednisolone alone, with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989, 44: 280-288. 21. Lerbow AA, Carrington CB. The eosinophitic pneumonias Medicine 1969; 48-251. 22. Myers LJ, Katzenstein Al. Microangitis in Lupus induced pulmonary hemorrhage. Am J Clin Patho 1986, 85; 552-556.